1. Pink Sheet

Market For COVID-19 Therapeutics Will Exceed Government Demand, US Believes

 
• By Derrick Gingery

HHS Secretary Azar says $1bn of the $2.5bn emergency supplemental funding request is for vaccine development.

Coronavirus
HHS Emergency Funding Request Covers Therapeutic Development, Ehanced US Surveillance • Source: Shutterstock

The vaccines and therapeutics developed to fight the COVID-19 outbreak are expected to find a broader market in the current crisis, unlike typical countermeasures.

The US federal Biomedical Advanced Research and Development Authority (BARDA) often is the only entity funding development and procurement of countermeasures for the strategic national stockpile,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.